Sanofi ADR (SNYN)

1,045.01
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    1,045.00/1,060.29
  • Day's Range:
    1,045.01 - 1,045.01

SNYN Overview

Prev. Close
1,040.95
Day's Range
1,045.01-1,045.01
Revenue
-
Open
1,045.01
52 wk Range
920-1,200
EPS
-
Volume
0
Market Cap
2.68T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,809
P/E Ratio
-
Beta
-
1-Year Change
-12.91%
Shares Outstanding
-
Next Earnings Date
-
What is your sentiment on Sanofi ADR?
or
Market is currently closed. Voting is open during market hours.

Sanofi ADR News

Sanofi ADR Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuySell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyNeutral

Sanofi ADR Company Profile

Sanofi ADR Company Profile

Employees
99412

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Read More
  • what is going on?why drop 4% inpremarket?
    0
    • NEWS: Sanofi agrees to make Moderna COVID-19 vaccine in the U.S. starting in September
      0
      • Announcement RIGHT NOW about a +$900 Million investment in Canada
        0
        • sanofi said it's vaccine will be available next year..
          0
          • but they have more products in pipeline...not just the vaccine
            0
        • Whi is it falling? FDA approval end its going down?
          0
          • Next target 52 buy at 48
            0
            • ARPO a small stock has given me 22% rise , that too on a day when all others have disappointed . Nova , Mrna , Bntx , Astra , Sanofi ... Seriously I salute to the guys running ARPO. .. its been so stable when all others are horribly unpredictable. ARPO has hd its base value and maintained its 1.5 level and Now its on 1.83 and after market is up again. highly recommended if someone wants to invest 1000 dollars and forget it for a while , I am sure its worth putting your 💰......
              0
              • https://ca.finance.yahoo.com/news/u-pay-2-1-billion-122206294.html
                0
                • TONIX PHARMACEUTICALS - WILL PRESENT CERTAIN INFORMATION REGARDING ITS VACCINE CANDIDATES TARGETING COVID-19 AT A  panel on may 19
                  3
                  • come on, you had good news today, why not going up?
                    0
                    • Companies upside looks unbelievable its the next awaiting Gilead. Partnering up with moderna, supporting the coronavirus outbreak with strong balance sheet. Its a must buy.
                      0
                      • President Donald Trump reportedly owns a stake in a company that produces hydroxychloroquine, the anti-malaria drug he has repeatedly touted as a coronavirus treatment even though his experts say there’s no strong evidence it works. 
                        2
                        • Dear Mr. Abbas Otobus., I would like to suggest you without any responsibility my personal investment to invest in Curetis NV and OpGen ., what do you think Sir ?
                          0
                          • Probably will gain too much in next 6 months because of using hydroxychloroquine for covid-19 prophylaxis and treatment
                            0
                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.